Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592382 | 0.81 | TDP1 (0.63) | NPSR1POLBTDP1MAPTKMT2A | |
| SCHEMBL8119880 | 0.80 | VCAM1 (0.58) | VCAM1TDP1MAPTKMT2AKAT2B | |
| SCHEMBL6887172 | 0.80 | NPSR1 (0.50) | VCAM1NPSR1POLBTDP1RAB9A | |
| SCHEMBL1970679 | 0.80 | NPSR1 (0.50) | NPSR1POLBTDP1MAPTGAA | |
| SCHEMBL30484019 | 0.80 | NPSR1 (0.50) | VCAM1NPSR1POLBTDP1RAB9A | |
| SCHEMBL30408370 | 0.79 | VCAM1 (0.45) | VCAM1NPSR1POLBTDP1MAPT | |
| SCHEMBL6882245 | 0.78 | NPSR1 (0.49) | NPSR1POLBTDP1MAPTKMT2A | |
| SCHEMBL25176277 | 0.78 | PLCG1 (0.48) | PLCG1KMT2AMEN1 | |
| SCHEMBL11216637 | 0.77 | PLCG1 (0.50) | PLCG1 | |
| SCHEMBL4009144 | 0.76 | NPSR1 (0.77) | NPSR1PLCG1POLBTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040146941-A1 | Chemical encoding technology for combinatorial synthesis | MASSACHUSETTS, UNIVERSITY OF | 2004-07-29 | — | — | US | disclosed |
| WO-2004041752-A2 | CHEMICAL ENCODING TECHNOLOGY FOR COMBINATORIAL SYNTHESIS | UNIVERSITY OF MASSACHUSETTS (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | VCAM1 2220/4885NPSR1 2205/4885PLCG1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.